The established plasmid, pGAD17, was introduced intoL.acidophilusNCK2208, the strain displaying MPER. system. In humans, 90% of intestinal and 50% of vaginal IgA is produced locally and induction of mucosal immunity is best achieved via mucosal infection or vaccination [13]. Passive transfer studies using broadly neutralizing antibodies (BnAb) have shown protection against mucosal transmission (reviewed in [4]). Induction of BnAb has proven extraordinarily difficult because neutralizing epitopes are often structurally complex and difficult to faithfully recapitulate, long-term immune maturation is needed to acquire the extensive hypermutation described for most neutralizing IgG, and some neutralizing antibodies show autoreactivity [5,6]. However, BnAb may not be essential for protection at the mucosa. There is strong evidence that protection by IgA typically does not rely on classical virus neutralization. IgA can sequester virus in mucus, sterically hinder binding to mucosal epithelia, and target virus for destruction via the polymeric immunoglobulin receptor (pIgR). There is also growing interest in the protective potential of non-neutralizing IgG [710]. Mechanisms of non-neutralizing protection include antibody-dependent cellular cytotoxicity, antibody-dependent cell-mediated virus inhibition, and other innate immune functions such as phagocytosis that are mediated by the Fc domain of the antibody. Whether BI 224436 mucosal vaccination can induce a protective antibody response of any sort against HIV-1 is uncertain. Lactobacilli are an important group of Gram positive lactic acid bacteria used for food preservation, food bioprocessing and as probiotics. Lactobacilli are increasingly under investigation as biologic vaccine vectors. Proof of principle studies have been performed using recombinant lactobacilli as oral vaccines against tetanus toxin, anthrax, rotavirus,Brucella aborus, SARS Coronavirus, human papilloma virus,Helicobacter pyloriand others (reviewed in [1113]). In 2003, Xin and colleagues employed recombinantLactococcus lactisto induce HIV-specific immune BI 224436 responses [14]. While this report clearly demonstrated the potential of lactic acid bacteria as vaccine vectors against HIV-1, there were two concerns with the approach that was employed. First, cholera toxin was used as an adjuvant and is not acceptable for use in humans. Second, the HIV-1 IIIB Env V2-V4 loop was used as the immunogen and is unlikely to induce a broadly protective immune response. Thus, alternative adjuvants and antigen design and expression are needed for a successful anti-HIV vaccine using lactic acid bacteria. We and others have shown that several cell surface components of the probiotic BI 224436 bacteria are recognized by immune cells via pattern recognition receptors [15]. In particular, lipoteichoic acid, peptidoglycan (PG), and muramyl dipeptide, the subcomponent of PG, are known Rabbit Polyclonal to Mouse IgG as the major immune stimulators recognized by the heterodimeric Toll-like receptor (TLR) 2/6 and nucleotide-binding oligomerization domain 2 (NOD2), respectively [1618]. This capacity to interact with the innate immune system explains why lactobacilli can effectively induce mucosal IgA (reviewed in [19]). The probiotic strainLactobacillus acidophilusNCFM is particularly promising as an oral vaccine vector because: (1) it is acid and bile tolerant; (2) it expresses mucus-binding proteins and associates with the intestinal mucosa; and (3) it binds to dendritic cells (DCs) through DC-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN) and other pattern BI 224436 recognition receptors described above [20]. Proof of principle has been demonstrated by Mohamadzadeh et al., who constructed recombinantL.acidophilusproducing theBacillus anthracisprotective antigen and succeeded in inducing protective immunity in a murine model [21]. For construction of recombinantL.acidophilusas a vaccine candidate, there are three strategies for the subcellular distribution of antigens: cytoplasmic accumulation, secretion, and cell surface display [12,22]. In this study, we inserted a linear epitope from the membrane proximal external region (MPER) of HIV-1 into the highly expressed bacterial surface layer protein (SlpA) ofL.acidophilus, as a prototype oral mucosal vaccine platform, and assessed immunogenicity in a mouse model. == Materials and Methods == == Ethics statement == This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, the US Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Protocol #11-3041A was approved by the Colorado State University Institutional Animal Care and Use Committee which operates under a currently approved Assurance #A3572-01. Animal welfare and health was monitored daily and in instances where medical intervention was not effective, animals were humanely euthanized and every effort was made to minimize suffering. == Bacterial strains and culture conditions == Lactobacillus acidophilusNCK1909 and derivative strains were grown statically in MRS BI 224436 broth (BD Diagnostics, Sparks, MD) alone or supplemented with.